Investigational drug · Phase 2
STL303
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for IgAN, Geographic Atrophy.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "STL303"
First trial start
2026
Aug 4, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "STL303", any sponsor or status.
Conditions studied
As listed on its trial records.
- IgAN
- Geographic Atrophy
Approved drugs for the same conditions: Geographic atrophy · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "STL303" as an intervention, largest first.
- A Study in Adults With Geographic AtrophyPivotal-lookingRecruiting
Sitala Bio LTDIndustry
NCT07606365 · 300 participants (planned) · Start Sep 11, 2026 · Primary completion Jul 2028
Drug: STL303; Placebo · For: Geographic Atrophy
Sites: Bakersfield, California; Beverly Hills, California; Aurora, Colorado · 56 sites in all
Sitala Bio LTDIndustry
NCT07606352 · 15 participants (planned) · Start Aug 4, 2026 · Primary completion Jul 2027
Drug: STL303; STL303 and 1 more · For: IgAN
Sites: Newcastle, Australia; Penrith, Australia; Sydney, Australia · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for IgAN
- siRNAADX-038, ADX-324Phase 37 trials
ADARx Pharmaceuticals, Inc. · Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1
- FXS6837Phase 34 trials
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Paroxysmal Nocturnal Hemoglobinuria, Primary IgAN, IgAN
- HS-10542Phase 22 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · IgAN, Immunoglobulin A Nephropathy (IgAN), Glomerular Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.